Posaconazole therapeutic drug monitoring in the real-life setting: A single-center experience and review of the literature

Pharmacotherapy

Volumn 33, Issue 10, 2013, Pages 1117-1125

  Gross, Barbara N ^a   Ihorst, Gabriele ^a   Jung, Manfred ^b   Wäsch, Ralph ^a   Engelhardt, Monika ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

antifungal prophylaxis; antifungals; posaconazole; therapeutic drug monitoring

Indexed keywords

ALANINE AMINOTRANSFERASE; POSACONAZOLE; VORICONAZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMATOLOGIC DISEASE; HUMAN; INCIDENCE; INVASIVE ASPERGILLOSIS; MALE; MUCOSA INFLAMMATION; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PREVALENCE; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SENESCENCE; SINGLE DRUG DOSE; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

ANTIFUNGAL PROPHYLAXIS; ANTIFUNGALS; POSACONAZOLE; THERAPEUTIC DRUG MONITORING;

ACADEMIC MEDICAL CENTERS; ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; ANTIFUNGAL AGENTS; DRUG MONITORING; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOSES; PROSPECTIVE STUDIES; RISK FACTORS; TRIAZOLES; YOUNG ADULT;

EID: 84900874866     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1328     Document Type: Review

References (21)

1. Jang SH, Colangelo PM, Gobburu JVS,. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115-9.
2. Andes D, Pascual A, Marchetti O,. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob Agents Chemother 2009; 53: 24-34.
3. Dolton MJ, Ray JE, Chen SC-A, Ng K, Pont L, McLachlan AJ,. Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration. Antimicrob Agents Chemother 2012; 56: 5503-10.
4. Crombag M-RBS, Huisman C, Kemper EM, Brüggemann RJM, Bijleveld YA,. Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. Ther Drug Monit 2012; 34: 320-5.
5. Eiden C, Meniane JC, Peyrière H, et al. Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. Eur J Clin Microbiol Infect Dis 2012; 31: 161-7.
6. Neubauer WC, Engelhardt M, König A, et al. Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. Antimicrob Agents Chemother 2010; 54: 4029-32.
7. Krishna G, Moton A, Ma L, Medlock MM, McLeod J,. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-66.
8. Bryant AM, Slain D, Cumpston A, Craig M,. A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis. Int J Antimicrob Agents 2011; 37: 266-9.
9. Neubauer W, König A, Bolek R, et al. Determination of the antifungal agent posaconazole in human serum by HPLC with parallel column-switching technique. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877: 2493-8.
10. Diggle PJ, Heagerty P, Liang K-Y, Zeger SL,. The analysis of longitudinal data. 2nd ed. Oxford: Oxford University Press; 2002.
11. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
12. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H,. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27: 1627-36.
13. Krishna G, AbuTarif M, Xuan F, Martinho M, Angulo D, Cornely OA,. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008; 28: 1223-32.
14. Lebeaux D, Lanternier F, Elie C, et al. Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. Antimicrob Agents Chemother 2009; 53: 5224-9.
15. Vaes M, Hites M, Cotton F, et al. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. Antimicrob Agents Chemother 2012; 56: 6298-303.
16. Tonini J, Thiébaut A, Jourdil JF, et al. Therapeutic drug monitoring of posaconazole: watch-out for gastrointestinal graft-versus-host disease. Antimicrob Agents Chemother 2012; 56: 5247-52.
17. Kohl V, Müller C, Cornely OA, et al. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 2010; 54: 207-12.
18. Shields RK, Clancy CJ, Vadnerkar A, et al. Posaconazole serum concentrations among cardiothoracic transplant recipients: factors impacting trough levels and correlation with clinical response to therapy. Antimicrob Agents Chemother 2011; 55: 1308-11.
19. Hoenigl M, Raggam RB, Salzer HJF, et al. Posaconazole plasma concentrations and invasive mould infections in patients with haematological malignancies. Int J Antimicrob Agents 2012; 39: 510-3.
20. Dolton MJ, Ray JE, Marriott D, McLachlan AJ,. Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 2012; 56: 2806-13.
21. Vehreschild JJ, Müller C, Farowski F, et al. Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome. Eur J Clin Pharmacol 2012; 68: 987-95.